

The Canadian Journal of Neurological Sciences



CAMBRIDGE
UNIVERSITY PRESS

Isolated, Subtle, Neurological Abnormalities in Mild Cognitive Impairment Types

Journal:	<i>The Canadian Journal of Neurological Sciences</i>
Manuscript ID	CJN-OA-2019-0148.R2
Manuscript Type:	Original Article
Date Submitted by the Author:	n/a
Complete List of Authors:	Camarda, Cecilia; University of Palermo, Department of Experimental Biomedicine and Clinical Neurosciences Camarda, Rosolino; University of Palermo, Department of Experimental Biomedicine and Clinical Neurosciences Pipia, Carmela; Fondazione Salvatore Maugeri, Fondazione Salvatore Maugeri Azzarello, Delia; University of Palermo, Department of Experimental Biomedicine and Clinical Neurosciences Grassedonio, Emanuele; University of Palermo, Department of Biomedicine, Neurosciences, and advanced Diagnostics, Section of Radiology Sottile, Gianluca; University of Palermo, Department of Economics, Business and Statistics Sciences Cilluffo, Giovanna; National Research Council, Institute of Biomedicine and Molecular Immunology Torelli, Paola; University of Parma, Department of Clinical and Experimental Medicine
Keywords:	Isolated, subtle, neurological abnormalities, Mild cognitive impairment types, White matter hyperintensities, Lacunes, Caudate atrophy, Global cerebral atrophy

SCHOLARONE™
Manuscripts

1 **Isolated, Subtle, Neurological Abnormalities in Mild Cognitive Impairment Types**

- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33

34 **Isolated, Subtle, Neurological Abnormalities in Mild Cognitive Impairment Types**

35

36

37

38 Cecilia Camarda¹, Rosolino Camarda², Carmela Pipia³, Delia Azzarello², Emanuele Grassedonio¹,

39 Gianluca Sottile⁴, Giovanna Cilluffo⁵, Paola Torelli⁶.

40

41

42

43

44

45 *¹ Department of Biomedicine, Neurosciences, and advanced Diagnostics, University of Palermo, Palermo,*

46 *Italy;*²*Department of Experimental Biomedicine and Clinical Neurosciences, University of Palermo,*

47 *Palermo, Italy;* ³*Fondazione “Salvatore Maugeri”, Sciacca, Italy;* ⁴*Department of Economics, Business,*

48 *and Statistics Sciences, University of Palermo, Palermo, Italy;* ⁵*Institute of Biomedicine and Molecular*

49 *Immunology, National Research Council, Palermo, Italy;* ⁶*Department of Clinical and Experimental*

50 *Medicine, University of Parma, Parma, Italy.*

51

52

53

54

55

56

57

58 *Correspondence to:*

59 Cecilia Camarda, Department of Biomedicine, Neurosciences, and advanced Diagnostics, University of

60 Palermo, via G. La Loggia,1-90139 Palermo, Italy. Email: cecilia.camarda@unipa.it

61 Gianluca Sottile, Department of Economics, Business, and Statistics Sciences, University of Palermo,

62 viale delle Scienze, bldg. 13, 90128 Palermo, Italy. Email: gianluca.sottile@unipa.it

63

64 **Abstract**

65

66 **Background:** Isolated, subtle neurological abnormalities (ISNA) are commonly seen in aging, and
67 have been related to cerebral Small Vessel Disease (SVD) and subcortical atrophy in neurologically
68 and cognitively healthy aging subjects.

69

70 **Objective:** To investigate the frequency of ISNA in different MCI types, and to evaluate for each
71 MCI type the cross-sectional relation between ISNA and white matter hyperintensities (WMH),
72 lacunes, caudate atrophy, and ventricular enlargement.

73

74 **Methods:** 1,250 subjects with different MCI types were included in the analysis, and underwent
75 brain MRI. WMH were assessed through two visual rating scales. Lacunes were also rated. Atrophy
76 of the caudate nuclei and ventricular enlargement were assessed through the bicaudate ratio (BCr)
77 and the lateral ventricles to brain ratio (LVBr), respectively. Apolipoprotein E (APOE) genotypes
78 were also assessed. The routine neurological examination was used to evaluate ISNA that were
79 clustered as central-based signs, cerebellar-based signs, and primitive reflexes. The items of Part-III
80 of the Unified Parkinson's Disease Rating Scale were used to evaluate ISNA that were clustered as
81 mild parkinsonian signs. Associations of ISNA with imaging findings was determined through
82 logistic regression analysis.

83

84 **Results:** The ISNA increase with the age, are present in all MCI types, particularly in those
85 multiple domains, and carrying the APOE $\epsilon 4$ allele, and are associated with WMH, lacunes, BCr,
86 and LVBr.

87

88 **Conclusion:** This study demonstrates that cortical and subcortical vascular and atrophic processes
89 contribute to ISNA. Long prospective population-based studies are needed to disentangle the role of
90 ISNA in the conversion from MCI to dementia.

91

92

93

94

95

96

97 **Keywords:** Isolated, subtle, neurological abnormalities, Mild cognitive impairment types, White matter
98 hyperintensities, Lacunes, Caudate atrophy, Global cerebral atrophy
99
100
101
102
103
104 Running title: ISNA in MCI types.
105
106
107
108
109
110
111 Words count of the title: 9
112 Words count of the title page: 132
113 Words count of the abstract: 247
114 Words count of the keywords: 18
115 Words count of the Introduction: 651
116 Words count of the Methods:1178
117 Words count of the Results: 1747
118 Words count of the Discussion:1189
119 Words count of the Conclusion:114
120 Words count of the body of the manuscript: **4879**
121
122 Total words of the manuscript: 5,277

123 INTRODUCTION

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

Mild cognitive impairment (MCI) is a term that refers to a condition in which an essentially spared global cognition, and normal or slightly impaired activities of daily living coexist with a mild decline of cognitive functions greater than that expected for age and education.^{1,2} Four MCI phenotypes have been recognized² as follows: amnesic MCI single domain (a-MCI), amnesic MCI multiple domain (a-MCI_{md}), nonamnesic MCI single domain (na-MCI), and nonamnesic MCI multiple domain (na-MCI_{md}). Extracellular deposition of β -amyloid ($A\beta$) peptide, intracellular deposition of hyperphosphorylated tau protein, and atrophy of frontal, parietal, and medial temporal cortices, *i.e.* neurodegeneration of AD signature cortical regions,³ are the key elements of the pathophysiology of Alzheimer disease (AD),⁴ and MCI due to AD.⁵ The prevalence of $A\beta$ positivity among subjects with MCI increases from age 50 to 90 years from 27% to 71%; nonamnesic MCI types have lower prevalence estimates of $A\beta$ positivity than amnesic MCI types, but higher than subjects cognitively normal (CN), and both amnesic and nonamnesic MCI are at increased risk for AD.⁶ Concerning tau, MCI and AD individuals have tau accumulation in the basal and mild-temporal, retrosplenial, posterior cingulate, and entorhinal regions greater than CN individuals $A\beta$ positive.⁷

The observation that 21,5% and 35% of individuals with amnesic and nonamnesic MCI types, respectively, are $A\beta$ negative,⁸ has suggested that these individuals are not on the AD pathway, and that vascular pathology may be one of the possible non-AD causes of MCI. Among vascular pathology, cerebral small vessel disease (SVD) plays a pivotal role. SVD affects the smallest cerebral small vessels, increases throughout the lifespan,⁹ and contributes to the risk of MCI,¹⁰ and dementia.¹¹ White matter hyperintensities (WMH), lacunes, small subcortical infarcts, microbleeds, enlarged perivascular spaces, and central atrophy are the imaging markers of SVD.¹² Lacunes¹³ and WMH¹⁴ disrupting locally the structural integrity of white matter induce thinning of the connected cortical regions through Wallerian degeneration. Lacunes are associated with widespread cortical thinning, atrophy in multiple subcortical structures, and ventricular enlargement.¹⁵ In subjects with MCI, expansion of the lateral ventricles is associated with atrophy of frontal, parietal, and temporal regions affected by AD.¹⁶ Furthermore, age *per se* is associated with atrophy of the cerebellum, striatum, and prefrontal, parietal, and temporal association cortices.¹⁷ The pattern of cortical atrophy induced by severe WMH overlaps substantially with the patterns of age-related cortical atrophy and of AD-related cortical atrophy.¹⁸ Since cortical

154 atrophy induced by WMH drives cognitive decline,¹⁹ age and SVD may contribute to the onset of
155 cognitive decline through the overlapping atrophy of cortical regions vulnerable to AD pathology.

156 Cerebral SVD, A β , tau, and atrophic changes fragmenting over time brain networks into
157 disconnected parts not only contribute to cognitive decline, but also contribute to the presentation of a
158 wide range of neurological signs. We have shown that neurologically and cognitively healthy (NCH)
159 aging subjects frequently present at the routine neurological examination isolated, subtle, neurological
160 abnormalities (ISNA) which do not have any immediate diagnostic relevance, cannot be attributed to any
161 definite, overt neurological disease, are associated with atrophy of the caudate nuclei, and with parietal
162 WMH and lacunes, and probably constitute a red flag for future cognitive decline given that they show
163 poor performance in test evaluating global cognition, executive function, and language.²⁰ Past reports on
164 neurological signs in MCI have primarily focused on extrapyramidal features,^{21,22} while reports on signs
165 others than extrapyramidal are sparse. Therefore, the aims of our study are: 1) to investigate the
166 prevalence of ISNA in the 4 MCI types; 2) to verify whether in the individual MCI types the
167 probability of having ISNA is differently associated with the topographical location of WMH and
168 lacunes, periventricular WMH (WMH-PV), APOE ϵ 4 allele, and with two linear measures of central
169 atrophy,¹² *i.e.* the bicaudate ratio (BCr) as proxy of subcortical atrophy, and the lateral ventricles to brain
170 ratio (LVBr) as proxy of global brain atrophy. In the present paper, the terms “adult”, “elderly”, “old”,
171 and “oldest-old” will be used to indicate people aged 45-64, 65-74, 75-84, and >85 years respectively.

172

173

174 **METHODS**

175 **Participants**

176 Data were used from the Cognitive Impairment through Aging (CogItA) study, a hospital-based
177 prospective study focused on normal and pathological aging in middle-aged and older individuals
178 launched in January, 2000. CogItA’s participants were outpatients self-referred or referred by general
179 practitioners for neurological and/or cognitive screenings to the clinics of the Department of Neurology
180 and Cognitive Disorders of the teaching Hospital (AOUP “P.Giaccone”) of the School of Medicine of the
181 University of Palermo, Italy. Details of the inclusion and exclusion criteria of the CogItA study have been
182 reported elsewhere.²⁰ Informed consent was obtained from all participants and relatives. The study was
183 approved by the University Hospital ethics committee, and complies with the declaration of Helsinki.

184 According to the published criteria,^{1,2} CogItA participants with preserved global cognition at the
185 Mini-Mental State examination (MMSE score $\geq 23,74$),²³ subjective cognitive concerns, objective
186 impairment in one or more cognitive domains, Clinical Dementia Rating (CDR) = 0.5),²⁴ no impaired or
187 minimally impaired functional status on the activities of daily living (ADL)²⁵ and the instrumental
188 activities of daily living (IADL) ²⁶ scales, and no dementia were classified as MCI and categorized as a-
189 MCI, a-MCI_{md}, na-MCI, and na-MCI_{md}. MCI subjects included in the present paper were stroke-free
190 first ever diagnosed cases (n=1,250) aged 45-95 years (mean age = 70,52 \pm 9,41 years), who remained in
191 the MCI status for at least 3 years (mean follow-up = 64,98 \pm 28,94 months). During this period, some of
192 these subjects changed their MCI typology, but in the present paper first-ever MCI diagnoses were
193 considered. Subjects who during the follow-up reverted to normal cognition, or converted to dementias
194 different from AD and Vascular Dementia (VaD) were not considered.

195

196 **Baseline Clinical Assessment**

197 Participants to the present study underwent an extensive assessment of variables such as
198 demographics, medical history, laboratory tests, neurological, and functional examinations, cognitive
199 testing, carotid ultrasonography, and brain magnetic resonance imaging (MRI). Many vascular risk
200 factors (VRF) and vascular diseases (VD) were considered and assessed as reported elsewhere.^{20,29} Since
201 multiple VRF and VD often coexist, we created the VRF and VD summary scores indicating for each
202 participant the sum of the individual VRF and VD that were concurrently present. APOE genotypes were
203 determined by using standard methods.³⁰ Participants with at least 1 APOE ϵ 4 allele were classified as
204 APOE ϵ 4 carriers.

205

206 **Assessment of ISNA**

207 All participants underwent a standardised neurological examination reflecting that routinely
208 performed in the clinical practice. Subjects presenting at baseline or during follow-up meaningful
209 neurological signs such as visual field defects, language deficits, cranial nerves deficits, hemimotor and
210 hemisensory dysfunction, brachial or crural weakness, brachial or crural sensory dysfunction, Babinski
211 sign, spastic rigidity, and hemiplegic gait were excluded. The ISNA evaluated were: 1) mild dysphagia, 2)
212 slurred speech, 3) central facial weakness, 4) mixed rigidity, *i.e.* a condition in which spastic and plastic
213 rigidity coexist; 5) hyperreflexia (bilateral increased deep tendon reflexes), 6) reflex asymmetry, 7)

214 tremor (resting tremor, and postural/kinetic tremor), 8) plastic rigidity, 9) bradykinesia, 10)
215 gait/balance/axial dysfunction, 11) dysmetria, 12) atactic type gait defined as a gait pattern broadly
216 indicative of cerebellar involvement, and 13) primitive reflexes (PR) *i.e.* glabellar tap, snout,
217 palmomental, grasping, and sucking reflexes.^{31,32} To evaluate tremor, rigidity, bradykinesia, and
218 gait/balance/axial dysfunction, collectively called Mild Parkinsonian Signs (MPS),³³ the items of motor
219 section of the Unified Parkinson's Disease Rating Scale (UPDRS)³⁴ were used, and were considered
220 present when any one of the following condition was met: (1) two or more items with a score of 1; or (2)
221 one item with a score ≥ 2 .²¹ The ISNA were dichotomised as absent (score = 0) or present (score = 1), and
222 were clustered into four categories as following: central-based signs (Cs) (signs 1-6), Mild Parkinsonian
223 Signs (MPS) (signs 7-10), cerebellar-based signs (CLs) (signs 11-12), and PR (signs 13). We defined the
224 presence of Cs, MPS, CLs, and PR as the presence of at least one sign within those included in each of
225 these clusters. Accordingly, subjects were divided into subjects without ISNA (ISNA-), and with ISNA
226 (ISNA+) if at least one sign within the above clusters was present. The neurological examination of each
227 participant was always performed by two neurologists blinded to the patients history and neuroimaging.
228 The interrater reliability assessed over time in random samples showed always excellent agreement with
229 weighted Cohen's kappa ranging between 0.88 and 0.91 ($p < 0.001$).

230

231 **Functional and Neuropsychological Assessments**

232 The functional status of participants was assessed through the ADL and the IADL scales. Cognitive
233 functions were assessed using an extensive neuropsychological battery as reported elsewhere,^{20,35}
234 including the MMSE as test of global cognition, and 12 tests to evaluate memory, attention, executive
235 function, language, constructional ability, and visuospatial skill. Impaired cognitive domains were
236 identified using a cut-off of 1,5 standard deviation (SD)² below the Italian normative data adjusted for
237 age-, sex-, and education.³⁶

238

239 **Carotid Ultrasonography and Imaging Assessments**

240 Intimal-medial thickness (IMT), and stenosis of internal carotid arteries (SICA) were assessed as
241 reported elsewhere.²⁰ Participants had brain MRI on a 1,5T scanner (GE Signa HDxt, Milwaukee, WI,
242 USA). Details of the image acquisition protocol have been published previously.²⁰ The BCr and the
243 LVBr were calculated as reported elsewhere.^{20,35} WMH, and lacunes were assessed according to the

244 published criteria.¹² The Wahlund scale (range 0-3) ³⁷ was used to obtain the scores of WMH of the
245 frontal, parieto-occipital, and temporal areas (WMH-SC), infratentorial (WMH-INF), basal ganglia
246 (WMH-BG), and the WMH total score (WMH-T). To define the WMH status, a cut-off score ≥ 2 in at
247 least one of the above regions was used. WMH-PV were evaluated with the Fazekas scale (range 0-3),³⁸
248 and a cut-off score ≥ 2 was used. Lacunes were assessed topographically according to the Wahlund
249 regions used to score WMH, and categorized as lacunes-SC, lacunes-BG, lacunes-INF, and lacunes-T. A
250 cut-off score ≥ 2 in at least one of the Wahlund regions was used to define the status of lacunes. Subjects
251 having WMH and/or lacunes with a score ≥ 2 in at least one of the Wahlund scale topographical locations
252 were categorized as SVD positive (SVD+), and those having WMH and/or lacunes with a score ≤ 1 were
253 categorized as SVD negative (SVD-).

254

255 **Statistical Analysis**

256 Descriptive statistics (percentages, mean and SD, median and IQR) were used to summarise data.
257 Continuous variables were compared between subjects ISNA- and ISNA+ by using one-way analysis of
258 variance (ANOVA), and differences were tested with a post hoc F-test. Categorical variables were
259 evaluated by contingency tables, and the hypotheses of independence were tested with χ^2 test. Logistic
260 ridge regression models³⁹ were used to evaluate for each MCI type the risk of having ISNA covarying for
261 age, sex, years of education, and the variables found significant in the univariate analysis. In general,
262 ridge regression method is the most applied solution for addressing problems of multicollinearity.⁴⁰ It
263 implies adding a small positive constant (λ), *i.e.* the ridge parameter, to the main diagonal elements of the
264 information matrix. The ridge parameter was selected using likelihood cross-validation.⁴¹ IMT, BC_r, and
265 LVBr values were scaled to work on percentage of increments. All tests were two-tailed, and statistical
266 significance was set at $p \leq 0.05$. Results are presented as odds ratios (ORs) with 95% confidence interval
267 (95% CI). All analyses were performed using R statistical software (version 3.5.1; The R Foundation for
268 Statistical Computing).

269

270

271 **RESULTS**

272 The demographic characteristics of the MCI types are shown in Table 1. In almost all MCI types,
273 the majority of subjects were elderly followed by old, adult, and oldest-old individuals. The MCI types

274 single domain were more common among the adults, while those multiple domain were more common
275 within the elderly, old, and oldest old participants. In each age class, the mean age didn't vary
276 significantly among the various MCI types. Since the oldest old subjects were few, subsequent analysis
277 was conducted pooling the old and oldest old classes in the class of old-oldest old.

278 Within the sample, 175 (14.0%) subjects didn't show any of the selected ISNA, while 1,075
279 (86.0%) presented at least one ISNA (Table 2). Overall, subjects ISNA- were more common among the
280 MCI types single domain, and subjects ISNA+ were more common among those multiple domain.
281 Primitive reflexes were the most frequent ISNA, followed by ISNA central-based, and mild parkinsonian
282 signs, while ISNA cerebellar-based were the rarest. PR were exhibited by 864 subjects (69.1%) of the
283 sample, and were more common among the MCI types multiple domain than those single domain. In all
284 MCI types, snout reflex was the most common PR followed by glabellar tap, and palmomentary reflex,
285 while grasping and sucking reflexes were the rarest. Snout and palmomentary reflexes were more common
286 among the MCI types multiple domain than those single domain, while glabellar tap was more common
287 among the amnesic MCI types than the nonamnesic types. The mean number of PR was greater among
288 the amnesic MCI types than the nonamnesic types. Central-based signs were exhibited by 645 subjects
289 (51,6%) of the sample. Subjects with Cs were more common among the nonamnesic MCI types than the
290 amnesic types. In all MCI types, reflex asymmetry was the most common Cs, followed by bilateral
291 hyperreflexia, central facial weakness, mixed rigidity, slurred speech, and dysphagia. Reflex asymmetry,
292 bilateral hyperreflexia, and central facial weakness were more common among the nonamnesic MCI
293 types than the amnesic types, while the frequency of the other Cs didn't vary among the 4 MCI types.
294 The mean number of Cs was greater among the nonamnesic MCI types than the amnesic types. Mild
295 Parkinsonian Signs were found in 46,2% (n=578) of the sample. In all MCI types, bradykinesia was the
296 most common MPS, followed by gait/balance/axial dysfunction, and tremor, while rigidity was the rarest.
297 Individual MPS were more common among the MCI types multiple domain than the MCI single domain.
298 The mean number of MPS was greater in the former than in the latter. Cerebellar-based signs were the
299 rarest ISNA encountered. Dysmetria was the most common CLs, and the atactic type gait was the rarest.
300 The frequency of dysmetria didn't vary among the 4 MCI types, while the atactic type gait was more
301 common among the a-MCI_{md} than the other MCI types. The mean number of CLs didn't vary among the
302 MCI types.

303 ISNA increased with age reaching a peak in the old-oldest old individuals (Table 3). Among the
304 adults, 210 subjects (65,8%) were ISNA+, and 109 subjects (34,2%) were ISNA-. PR were the most
305 frequent ISNA followed by Cs, MPS, and CLs categories. PR, Cs, and MPS were more common among
306 the MCI types multiple domain than those single domain, while CLs didn't vary in the 4 MCI types. The
307 mean number of ISNA was greater in the former than in the latter. Within the elderly, 405 subjects
308 (88,4%) were ISNA+, and 53 subjects (11,6%) were ISNA-. The frequency of subjects ISNA+ didn't
309 vary among the 4 MCI types. PR were the most frequent ISNA followed by Cs, MPS, and CLs categories.
310 PR were almost equally distributed in the 4 MCI types, MPS and CLs were more common among the
311 MCI types multiple domain, and Cs were more common among the nonamnestic MCI types. The mean
312 number of ISNA was greater in the nonamnestic MCI types, than in the amnestic types. Among the old-
313 oldest old subjects, 461 individuals (97,5%) presented at least one ISNA, and 12 individuals only (2,5%)
314 were ISNA-. CLs and MPS didn't vary among the 4 MCI types. Cs were significantly more common
315 among the nonamnestic MCI types, while PR were significantly more common among the amnestic MCI
316 type. The mean number of ISNA was significantly greater in the na-MCIImd type than in the other MCI
317 types. The co-occurrence of multiple ISNA increased with age in all MCI types.

318 Baseline characteristics of MCI types ISNA+ and ISNA- are shown in Table 4. In all MCI types, no
319 difference was found in the distribution of female and male among the two ISNA groups. In all MCI
320 types, the mean age of female was greater in subjects ISNA+ than in subjects ISNA-, while the mean
321 age of male was greater in subjects ISNA+ than in subjects ISNA- in the a-MCI only. Level of education
322 didn't vary among the ISNA groups in MCI types single domain and in a-MCIImd type, while in the na-
323 MCIImd type subjects ISNA+ were less educated than subjects ISNA-. The ADL scores were worse in
324 the MCI types single domain ISNA+ only, and the IADL scores were worse in the MCI types single
325 domain and a-MCIImd ISNA+. In the na-MCIImd type, ADL and IADL scores didn't vary among the two
326 ISNA groups. Out of the VRF evaluated, arterial hypertension only was significantly more common
327 among subjects ISNA+ than subjects ISNA- with the na-MCIImd type, while no difference was found in
328 the distribution of VRF among the two ISNA groups of the other MCI types. However, in a-MCI and na-
329 MCIImd, the VRF summary score was greater in subjects ISNA+ than those ISNA-. No difference was
330 found in the frequency of the VD evaluated among subjects ISNA+ and ISNA- of almost all MCI types,
331 with the exception of history of TIA that was significantly more common among the subjects a-MCI
332 ISNA+. The VD summary score was greater in subjects ISNA+ than in those ISNA- in the a-MCI only.

333 In the a-MCI type, APOE ϵ 4 carriers were significantly more common in subjects ISNA+ than in subjects
 334 ISNA-, and APOE ϵ 4 non carriers were significantly more common in subjects ISNA- than in subjects
 335 ISNA+. The distribution of APOE ϵ 4 carriers and non carriers didn't differ in the two ISNA groups of the
 336 other MCI types.

337 Neuropsychological performances of MCI types ISNA+ and ISNA- are summarized in Table 5. The
 338 MMSE score was above the cut-off level in all MCI types, but subjects a-MCI ISNA+ performed
 339 significantly less than subjects ISNA-. As expected, a worse performance on memory task was exhibited
 340 by the amnesic MCI types ISNA+ and ISNA-. In subjects with a-MCI, the nonmemory domains were not
 341 impaired, but subjects ISNA+ performed significantly less than subjects ISNA- in attention, executive
 342 function, and language. In subjects a-MCI_{md} ISNA+ and ISNA-, the nonmemory domains were
 343 impaired, and subjects ISNA+ performed significantly worse than subjects ISNA- in tests evaluating
 344 language. In the nonamnesic MCI types no significant difference was found in the performance of
 345 nonmemory domains among subjects ISNA+ and ISNA-, although a trend of worse performance of
 346 subjects ISNA+ in almost all cognitive domains was evident.

347 Carotid ultrasonography and imaging findings in the MCI types ISNA+ and ISNA- are reported in
 348 Table 6. In all MCI types, the frequency of IMT was significantly higher in subjects ISNA+ than
 349 subjects ISNA-, while the frequency of SICA didn't differ between the two ISNA groups. In a-MCI, na-
 350 MCI, and na-MCI_{md}, WMH-SC, WMH-T, and WMH-PV were significantly higher in subjects ISNA+
 351 than subjects ISNA-, while in a-MCI_{md} WMH-BG only were significantly higher in subjects ISNA+.
 352 Lacunes-BG and lacunes-T were significantly higher in MCI types single domain ISNA+, and lacunes-T
 353 were significantly higher in na-MCI_{md} ISNA+. In a-MCI, na-MCI, and na-MCI_{md}, SVD+ was more
 354 common in subjects ISNA+ than ISNA-, while SVD- was more common among the subjects ISNA- than
 355 ISNA+. In a-MCI_{md}, the distribution of subjects SVD+ and SVD- didn't differ among the two ISNA
 356 groups. BCr was significantly higher in all MCI types ISNA+ with the exception of a-MCI_{md} type. LVBr
 357 was significantly higher in the MCI types single domain ISNA+, while no difference among the ISNA
 358 groups was found in the MCI types multiple domains.

359 To assess the effects of the variables evaluated on the estimated probability of having at least one
 360 ISNA, logistic ridge regression analysis was carried out in each MCI type (Table 7). Age resulted
 361 associated with a-MCI type only. For each year of age increase, the odds of having at least one ISNA
 362 went up about 3%. Being female increased by 7,7% the probability of having at least one ISNA in the a-

363 MCI type only. Education, and VRF summary score didn't influence the probability of having at least one
 364 ISNA in any of the MCI types. VD summary score increased the probability of having at least one ISNA
 365 in a-MCI (18,1%), na-MCI (11,1%), and na-MCIImd (4,5%). Being carrier of the APOE ϵ 4 allele
 366 increased by 52,7%, 16,5%, and 5,1% the probability of having at least one ISNA in a-MCI, a-MCIImd,
 367 and na-MCIImd, respectively. At the increase of a single percentage point of the IMT the probability of
 368 having at least one ISNA in a-MCI, a-MCIImd, na-MCI, and na-MCIImd went up by 52,7%, 36,9%,
 369 14,8%, and 16,3%, respectively. The presence of WMH-PV increased by 36,7%, 58,4%, and 14,3% the
 370 probability of having at least one ISNA in a-MCI, na-MCI, and na-MCIImd, respectively. The presence
 371 of SVD in the frontal region increased the risk of having at least one ISNA in a-MCI (16,4%), na-MCI
 372 (54,5%), and na-MCIImd (16%) types. The presence of SVD in the parieto-occipital region increased the
 373 risk of having at least one ISNA in a-MCI, na-MCI, and na-MCIImd by 22,3%, 30,3%, and 10,5%,
 374 respectively. The presence of SVD in the lateral temporal region increased the risk of having at least one
 375 ISNA in a-MCI, a-MCIImd, na-MCI, and na-MCIImd MCI by 14,0%, 15,9%, 19,8%, and 8,4%,
 376 respectively. The presence of SVD in the basal ganglia increased the risk of having at least one ISNA in
 377 a-MCI, a-MCIImd, na-MCI, and na-MCIImd by 29,9%, 31,1%, 51,8%, and 9,7%, respectively. BCr, and
 378 LVBr resulted associated with all the MCI types. At the increment of a single percentage point of BCr,
 379 the probability of having at least one ISNA increased by 15,6% in a-MCI, 31,9% in a-MCIImd, 65,8% in
 380 na-MCI, and 32,4% in na-MCIImd. At the increment of a single percentage point of LVBr, the odds of
 381 having at least one ISNA increased by 13,1% in a-MCI, 6,2% in a-MCIImd, 9,6% in na-MCI, and 5,2% in
 382 na-MCIImd.

383
 384
 385

DISCUSSION

386 The frequency of ISNA detected in subjects with MCI was greater (86%) than that found in NCH
 387 aging individuals (57,2%).²⁰ In all MCI types, and in all age classes, PR were the ISNA most frequently
 388 encountered, followed by Cs, MPS, and CLs. All ISNA categories increased with age, and were presented
 389 by both the amnesic and nonamnesic MCI types, particularly by those multiple domain, with the
 390 exception of Cs and PR that in the old-oldest old subjects were more common among the MCI types
 391 single domain.

392 Copious data of the literature underline the importance of midlife vascular risks and A β burden to
 393 neurodegenerative processes, and to the development of cognitive decline in older adults. In CN

394 individuals, midlife VRF accelerate structural brain aging,⁴² are associated with greater prospective
395 cognitive decline,⁴³ current and later-life smaller brain volumes,⁴⁴ and risk of dementia.⁴⁵ Further, midlife
396 but not later-life exposure to VRF is important also for A β deposition, as shown by the fact that having 2
397 or more midlife VRF compared with none is significantly associated with elevated A β deposition (61.2%
398 vs 30.8%).⁴⁶ In addition, in CN and MCI individuals, VRF interact with A β to reduce cortical thickness
399 in frontotemporal and parietal regions vulnerable to AD,⁴⁷ and are associated with prospective cognitive
400 decline, both alone and synergistically with A β burden.⁴⁸ However, VRF summary score was not
401 associated with ISNA in any of the 4 MCI types, and VD summary score increased the probability of
402 having at least one ISNA in the MCI types single domain, and poorly in the na-MCI_{md}. These data need
403 attention. A high vascular risk burden at younger ages is indeed indicative of early vascular aging,⁴⁹ but in
404 the later years of life it is less relevant regarding the MCI typology since vascular and neurodegenerative
405 processes have already occurred at younger ages when the MCI typology is likely to be of single domain
406 type. The fact that subjects with MCI types multiple domain were older than subjects with MCI types
407 single domain supports this hypothesis. IMT increased the probability of having at least one ISNA in all
408 MCI types, and the risk was greater for the amnesic MCI types than for the nonamnesic types. These
409 results are in agreement with a previous study showing that IMT is associated with WMH, infarcts, brain
410 atrophy, and with poor cognitive performance particularly in the executive function.⁵⁰ Further, IMT
411 significantly increases the risk of conversion of a-MCI to dementia.⁵¹ WMH-PV increased greatly the
412 probability of having at least one ISNA in MCI types single domain, and in the na-MCI_{md}. It has been
413 shown that WMH-PV are associated with elevated A β deposition independently from age and presence of
414 APOE ϵ 4 allele,⁵² and induce thinning of prefrontal, parietal, temporal cortices, anterior insula, and
415 atrophy of the caudate nuclei,¹⁴ and cognitive decline through the cortical atrophy of the above
416 disconnected regions.¹⁹ Therefore, it is reasonable to suspect that even in our MCI types WMH-PV may
417 also have induced atrophy of the caudate nuclei, and thinning of the frontal, parietal, and temporal
418 cortices through likely disruption of periventricular long associating tracts.

419 Overall, SVD at different topographical locations, and BCr greatly increases the risk of having
420 ISNA in all the MCI types. Given that cortex, cerebellum, and BG are strictly interconnected,⁵³ it is
421 likely that ISNA are the by-product of the disconnection of the cortical-cerebellar-basal ganglia-thalamo-
422 cortical circuits induced by vascular and degenerative processes. It is also likely that the caudate atrophy
423 and the disruption of the internal circuits of BG may have induced an excessive inhibition to its output

424 nuclei. As a consequence, the inhibitory drive to thalamus may have led to bradykinesia, and that to
425 brainstem structures controlling postural muscle tone and locomotion may have led to rigidity and
426 gait/balance/axial dysfunction respectively,⁵⁴ while the inhibition of the physiological inhibitor control of
427 lower brainstem centres on stereotyped motor responses⁵⁵ may have led to the reappearance of PR.

428 Nevertheless, the above hypotheses underpinning the vascular contribution to ISNA do not fully
429 explain their presentation in the various MCI types. Among the amnesic MCI types, 39% (n=342) of
430 subjects ISNA+ were SVD-, and 5% (n=45) of subjects ISNA- were SVD+. Similarly, among the
431 nonamnesic MCI types 51% (n=190) of subjects ISNA+ were SVD-, and 35% (n=130) of subjects
432 ISNA- were SVD+. These conflicting data suggest that co-occurring factors others than vascular
433 contribute to the presentation of ISNA. The APOE ϵ 4 allele can be one of these factors. In the present
434 study, the APOE ϵ 4 carriers were indeed over-represented relative to other studies, probably because the
435 CogItA study assessed essentially subjects referred to the memory clinic, making the sample vulnerable
436 to selection. Overall, APOE ϵ 4 carriers were more common among subjects ISNA+ than subjects ISNA-
437 in all MCI types, and being ϵ 4 carrier increased the probability of having at least one ISNA greatly in the
438 amnesic MCI types and scarcely in the nonamnesic MCI types, a finding in agreement with the notion
439 that compared to non ϵ 4 carriers, MCI ϵ 4 carriers have frequently the amnesic phenotype.⁵⁶ The presence
440 of APOE ϵ 4 allele in nonamnesic MCI types is not surprising. Along with age, APOE ϵ 4 allele is a
441 significant predictor of amyloidosis. More than half of all MCI types is A β positive,⁵⁷ and APOE ϵ 4
442 carriers are 2-3 times more likely to be amyloid positive than APOE ϵ 4 non carriers.⁶ Subjects with MCI
443 have elevated A β deposition in frontal, parietal, temporal, and posterior cingulate cortices suggestive of
444 early AD process,⁵⁸ and those converting to AD have a greater A β deposition in these regions, as well as
445 in the putamen and in the caudate nuclei as compared to nonconverters.⁵⁹ Furthermore, in subjects with
446 MCI the presence of the APOE ϵ 4 allele is more frequent in the converters than in the nonconverters.⁶⁰
447 Therefore, it is reasonable to suspect that subjects of all 4 MCI types carrying the APOE ϵ 4 allele were
448 also A β positive, and that subjects ISNA+ being more APOE ϵ 4 carriers than subjects ISNA- were
449 candidates to convert to dementia faster than subjects ISNA-.

450

451 **Limitations of the study**

452 Some limitations of our study are worth noting. First, CSF biomarkers of A β and tau, and
453 advanced imaging techniques up to now are not fully available in our country, particularly in a clinical

454 setting. So, we do not know the distribution of A β and tau in subjects ISNA+ and ISNA- of the various
455 MCI types. Second, we assessed cortical and subcortical atrophy using linear measurements well aware
456 that they are rather crude estimates of brain atrophy. However, it has been shown that the bicaudate ratio
457 is a reliable marker of caudate atrophy,⁶¹ and that ventricular enlargement is a feasible, even if
458 nonspecific, surrogate marker of neurodegeneration in MCI and AD.¹⁶ Third, we didn't estimate WMH
459 volumetrically, but visually. However, it has been shown that WMH evaluated with visual scales correlate
460 well with WMH volumetry.⁶² Fourth, perhaps we underestimated the magnitude of cerebral SVD in our
461 cohort, because we evaluated WMH and lacunes only. Fifth, the generalizability of our results is limited
462 because the patients have been selected in a hospital setting. Sixth, in the present paper there is not
463 mention of the ISNA in neurologically and cognitively normal subjects because data on this topic has
464 been already published.²⁰ Lastly, the cross-sectional design of our study doesn't allow causal inferences.

465

466 CONCLUSION

467 ISNA are likely to have a multifactorial origin, increase with age, and are presented by both the
468 amnesic and nonamnesic MCI types, particularly by those multiple domain, and carrying the APOE ϵ 4
469 allele. Further, subjects ISNA+ perform less than subjects ISNA- in almost all nonmemory domains.
470 Given that cortical and subcortical vascular and atrophic processes contribute to ISNA, their presence in
471 individuals with MCI must alert the practitioners to target timely interventions to slowing cognitive
472 decline and delay progression of MCI to dementia. Longer prospective population-based studies are
473 needed to clarify to what extent the presentation of ISNA in middle-aged and older MCI individuals
474 represents an additive risk for the conversion to dementia.

475

476

477

478

479

480

481

482

483

484 **ACKNOWLEDGEMENTS**

485 We gratefully thank all participants, as well as the neurologists and the neuropsychologists who over time
486 collected patients data.

487

488 **STATEMENT OF AUTHORSHIP**

489 CC and RC were responsible for the study's concept and design, data managements, and record linkage.

490 GS and GC did the statistical analysis. CC, PT, CP, DA, and RC contributed to the analysis and
491 interpretation of the data.

492 CC wrote the paper. All co-authors edited the paper, and approved its final version.

493

494

495 **DISCLOSURES**

496 All the authors hereby declare that they have nothing to disclose.

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

REFERENCES

532

1. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. *Arch Neurol.* 1999; 56:303-308.
2. Petersen RC. Mild cognitive impairment as a diagnostic entity. *J Intern Med.* 2004; 256:183-194.
3. Jack RC Jr. Brain Atrophy on Magnetic Resonance Imaging as a Biomarker of Neurodegeneration. *JAMA Neurol.* 2006; 73:1179-1182.
4. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guide-lines for Alzheimer's disease. *Alzheimers Dement.* 2001; 7: 263-269.
5. Albert MS, Dekosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging and Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement.* 2011; 7:270-279.
6. Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FR, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. *JAMA* 2015; 313:1924-1938.
7. Jack CR Jr, Wiste HJ, Schwarz CG, Lowe VJ, Senjem ML, Vemuri P, et al. Longitudinal tau PET in ageing and Alzheimer's disease. *Brain.* 2018; 141: 1517-1528.
8. Petersen RC, Aisen P, Boeve BF, Geda YE, Ivnik RJ, Knopman DS, et al. Criteria for mild cognitive impairment due to Alzheimer disease in the community. *Ann Neurol.* 2013; 74:199-208.
9. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. *Lancet Neurol.* 2010; 9: 689-701.
10. Luchsinger JA, Brickman AM, Reitz C, Cho SJ, Schupf N, Manly JJ, et al. Subclinical cerebrovascular disease in mild cognitive impairment. *Neurology.* 2009; 73:450-456.
11. Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke.* 2011; 42:2672-2713.
12. Wardlaw JM, Smith C, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, et al. Neuroimaging standards

- for research into small vessel disease and its contribution to ageing and neurodegeneration. *Lancet Neurol.* 2013; 12: 822-838.
13. Reijner YD, Freeze WM, Leemans A, Biessels GJ. The effect of lacunar infarcts on white matter tract integrity. *Stroke.* 2013; 44:2019-2021.
 14. Lambert C, Narean JS, Benjamin P, Zeestraten E, Barrick TR, Markus HS. Characterising the grey matter correlates of leukoaraiosis in cerebral small vessel disease. *Neuroimage Clin.* 2015; 9:194-205.
 15. Thong JY, Hilal S, Wang Y, Soon HW, Dong Y, Collinson SL, et al. Association of silent lacunar infarct brain atrophy and cognitive impairment. *J Neurol Neurosurg Ps.* 2013; 84:1219-1225.
 16. Madsen SK, Gutman BA, Joshi SH, Toga AW, Jack CR Jr, Weiner MW, et al. Mapping ventricular expansion onto cortical gray matter in older adults. *Neurobiol Aging.* 2014; 36 (Suppl 1): S32-S41.
 17. Raz N, Lindenberger U, Rodrigue KM, Kennedy KM, Head D, Williamson A, et al. Regional brain changes in aging healthy adults: general trends, individual differences and modifiers. *Cereb Cortex.* 2005; 15: 1676-1689.
 18. Habes M, Erus G, Toledo JB, Zhang T, Bryan N, Launer LJ, et al. White matter hyperintensities and imaging patterns of brain ageing in the general population. *Brain.* 2016; 139: 1164-1179.
 19. Rizvi B, Narkhede A, Last BS, Budge M, Tosto G, Manly JJ, et al. The effect of white matter hyperintensities on cognition is mediated by cortical atrophy. *Neurobiol Aging.* 2018; 64: 25-32.
 20. Camarda C, Torelli P, Camarda R, Battaglini J, Gagliardo C, Monastero R. Isolated, Subtle, Neurological Abnormalities in Neurologically and Cognitively Healthy Aging Subjects. *J Neurol.* 2015; 262:1328-1339.
 21. Louis ED, Schupf N, Manly J, Marder K, Tang MX, Mayeux R. Association between mild parkinsonian signs and mild cognitive impairment in a community. *Neurology.* 2005; 64:1157-1161.
 22. Boyle PA, Wilson RS, Aggarwal NT, Arvanitakis Z, Kelly J, Bienias JL, et al. Parkinsonian signs in subjects with mild cognitive impairment. *Neurology.* 2005; 65:1901-1906.
 23. Folstein MF, Folstein SE, McHugh PR. Mini-mental State: a practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res.* 1975; 12:189-198.
 24. Morris JC. Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. *Int Psychogeriatr.* 1997; 9:173-176.
 25. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the aged. The index of

- ADL: a standardized measure of biological and psychosocial function. *JAMA*. 1963; 185: 914-919.
26. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. *Gerontologist*. 1969; 9:179-186.
 27. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. *J Alzheimers Dis*. 2006; 9: 417-423.
 28. Brun A, Englund B, Gustafson L, Passant U, Mann DMA, Neary D, et al. Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups. *J Neurol Neurosurg Psychiatry*. 1994; 57: 416-418.
 29. Camarda C, Torelli P, Pipia C, Azzarello D, Battaglini I, Sottile G, Cilluffo G, Camarda R. Nociceptive primitive reflexes in neurologically and cognitively healthy aging subjects. *Canad J Neurol Sci*. 2019; 46:199-208.
 30. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. *J Lipid Res*. 1982; 31: 545-548.
 31. Rossor MN. Snouting, potting and rooting. *Pract Neurol*. 2001; 1:119-121.
 32. Schott JM, Rossor MN. The grasp and other primitive reflexes. *J Neurol Neurosurg Psychiatry*. 2003; 74:558-560.
 33. Louis ED, Bennett DA. Mild Parkinsonian Signs: an overview of an emerging concept. *Mov Disord*. 2007; 22:1681-1688.
 34. Fahn S, Elton RL and the members of the UPDRS development committee. Unified Parkinson's Disease Rating Scale. In Fahn S, Marsden CD, Goldstein M, Calne DB (Eds). *Recent Developments in Parkinson's Disease*. London, MacMillan Healthcare Information pp. 153-163 (1987).
 35. Camarda C, Pipia C, Azzarello D, Battaglini I, Romeo G, Chiodi M, et al. Vascular Risk Factors, Vascular Diseases, and Imaging Findings in a Hospital-based Cohort of Mild Cognitive Impairment Types. *Current Alzheimer Dis*. 2018; 15: 679-690.
 36. Carlesimo GA, Caltagirone C, Gainotti G. The Mental Deterioration Battery: normative data, diagnostic reliability and qualitative analyses of cognitive impairment: the Group for the Standardization of the Mental Deterioration Battery. *Eur Neurol*. 1996; 36: 378-384.
 37. Wahlund LO, Barkhof F, Fazekas F, Bronge L, Augustin M, Sjögren M, et al. A new rating scale for

- age-related white matter changes applicable to MRI and CT. *Stroke*. 2001; 32: 1318-1322.
38. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. *AJR Am J Neuroradiol*. 1987; 8:421-426.
 39. Hoerl AE, Kennard RW. Ridge regression: Biased estimation for nonorthogonal problems. *Technometrics*. 1970; 12: 55-67.
 40. El-Dereny M, Rashwan NI. Solving multicollinearity problem using ridge regression models. *Int J Contemp Math Sciences*. 2011; 6: 585-600.
 41. Goeman JJ. L1 penalized estimation in the Cox proportional hazards model. *Biom J*. 2010; 52:70-84.
 42. Debette S, Seshadri S, Beiser A, Au R, Himalim JJ, Palumbo C, et al. Midlife vascular risk factor exposure accelerates structural brain aging and cognitive decline. *Neurology*. 2011; 77:461-468.
 43. Gottesman RF, Schneider AL, Albert M, Alonso A, Bandeen-Roche K, Coker L, et al. Midlife hypertension and 20-year cognitive change: the atherosclerosis risk in communities neurocognitive study. *JAMA Neurol*. 2014; 71:1218-1227.
 44. Pase MP, Davis-Plourde K, Himali JJ, Satizabal CL, Aparicio H, Seshadri S, et al. Vascular risk at younger ages most strongly associates with current and future brain volume. *Neurology*. 2018; 91: 1479-1486.
 45. Whitmer RA, Gunderson EP, Quesenberry CP Jr, Zhou J, Yaffe K. Bodymass index in midlife and risk of Alzheimer disease and vascular dementia. *Curr Alzheimer Res*. 2007; 4:103-109.
 46. Gottesman RF, Schneider AL, Zhou Y, Coresh J, Green E, Gupta N, et al. Association between midlife vascular risk factors and estimated brain amyloid deposition. *JAMA*. 2017; 317:1443-1450.
 47. Villeneuve S., Reed BR, Madison CM, Wirth M, Marchant NL, Kriger S, et al. Vascular risk and A β interact to reduce cortical thickness in AD vulnerable brain regions. *Neurology*. 2014; 83: 40-47.
 48. Rabin JS, Schultz AP, Hedden T, Viswanathan A, Marshall GA, Kilpatrick E, et al. Interactive Associations of Vascular Risk and β -Amyloid Burden With Cognitive Decline in Clinically Normal Elderly Individuals. Findings From the Harvard Aging Brain Study. *JAMA Neurol*. 2018; 75: 1124-1131.
 49. Nilsson PM. Early vascular aging (EVA): consequences and prevention. *Vasc Health Risk Manag*. 2008; 4:547-552.
 50. Romero JR, Beiser A, Seshadri S, Benjamin EJ, Polak JF, Vasan RS, et al. Carotid artery

- atherosclerosis, MRI indices of brain ischemia, aging, and cognitive impairment: the Framingham study. *Stroke*. 2009; 40:1590-1596.
51. Viticchi G, Falsetti L, Vernieri F, Altamura C, Bartolini M, Luzzi S, et al. Vascular predictors of cognitive decline in patients with mild cognitive impairment. *Neurobiol Aging*. 2012; 33: 1127. e1-9.
 52. Marnane M, Al-Jawadi OO, Mortazavi S, Pogorzelec KJ, Wang BW, Feldman HH, et al. Periventricular hyperintensities are associated with elevated cerebral amyloid. *Neurology*. 2016; 86:1-9.
 53. Caligiore D, Strick PL, Jörntell H, Popa T, Herreros I, Pezzulo G, et al. Consensus Paper: Towards a Systems-Level View of Cerebellar Function: the Interplay Between Cerebellum, Basal Ganglia, and Cortex. *Cerebellum*. 2017; 16:203-229.
 54. Takakusaki K. Neurophysiology of gait: from the spinal cord to the frontal lobe. *Mov Disord*. 2013; 28:1483-1491.
 55. Delwaide PJ, Dijeux L. Réflexes néonataux et dyskinésies bucco-linguo-faciales dans la démence sénile. Neonatal reflexes and bucco-linguo-facial dyskinesias in senile dementia. *L'Actualité en Gériatrie*. 1980; 6:126-33.
 56. Snowden JS, Stopford CL, Julien CL, Thompson JC, Davidson Y, Gibbons L, et al. Cognitive phenotypes in Alzheimer's disease and genetic risk. *Cortex*. 2007; 43:835-845.
 57. Wolk DA, Price JC, Saxton JA, Snitz BE, James JA, Lopez OL, et al. Amyloid imaging in mild cognitive impairment subtypes. *Ann Neurol*. 2009; 65:557-568.
 58. Kemppainen NM, Aalto S, Wilson IA, Någren K, Helin S, Brück A, et al. PET amyloid ligand [C-11] PIB uptake is increased in mild cognitive impairment. *Neurology*. 2007; 68:1603-1606.
 59. Koivunen J, Scheinin N., Virta JR, Aalto S, Vahlberg T, Någren K, et al. Amyloid PET imaging in patients with mild cognitive impairment. A 2-year follow-up study. *Neurology*. 2011; 76:1085-1090.
 60. Okello A, Koivunen J, Edison P, Archer HA, Turkheimer FE, Någren K, et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. *Neurology*. 2009; 73:754-760.
 61. Doraiswamy PM, Patterson L, Na C, Husain MM, Boyko O, McDonald WM, et al. Bicaudate index on magnetic resonance imaging: effects of normal aging. *J Geriatr Psych Neurol*. 1994; 7: 13-17.
 62. Gao F, Swartz RH, Scheltens P, Leibovitch FS, Kiss A, Honjo K, et al. Complexity of MRI White matter

hyperintensity assessments in relation to cognition in aging and dementia from the Sunnybrook
Dementia Study. *J Alzheimers Dis.* 2011; 26: 379-388.

533

1 **Isolated, Subtle, Neurological Abnormalities in Mild Cognitive Impairment Types**

2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33

34 **Isolated, Subtle, Neurological Abnormalities in Mild Cognitive Impairment Types**

35

36

37

38 Cecilia Camarda¹, Rosolino Camarda², Carmela Pipia³, Delia Azzarello², Emanuele Grassedonio¹,

39 Gianluca Sottile⁴, Giovanna Cilluffo⁵, Paola Torelli⁶.

40

41

42

43

44

45 *¹ Department of Biomedicine, Neurosciences, and advanced Diagnostics, University of Palermo, Palermo,*

46 *Italy;*²*Department of Experimental Biomedicine and Clinical Neurosciences, University of Palermo,*

47 *Palermo, Italy;* ³*Fondazione “Salvatore Maugeri”, Sciacca, Italy;* ⁴*Department of Economics, Business,*

48 *and Statistics Sciences, University of Palermo, Palermo, Italy;* ⁵*Institute of Biomedicine and Molecular*

49 *Immunology, National Research Council, Palermo, Italy;* ⁶*Department of Clinical and Experimental*

50 *Medicine, University of Parma, Parma, Italy.*

51

52

53

54

55

56

57

58 *Correspondence to:*

59 Cecilia Camarda, Department of Biomedicine, Neurosciences, and advanced Diagnostics, University of

60 Palermo, via G. La Loggia,1-90139 Palermo, Italy. Email: cecilia.camarda@unipa.it

61 Gianluca Sottile, Department of Economics, Business, and Statistics Sciences, University of Palermo,

62 viale delle Scienze, bldg. 13, 90128 Palermo, Italy. Email: gianluca.sottile@unipa.it

63

64 **Abstract**

65

66 **Background:** Isolated, subtle neurological abnormalities (ISNA) are commonly seen in aging, and
67 have been related to cerebral Small Vessel Disease (SVD) and subcortical atrophy in neurologically
68 and cognitively healthy aging subjects.

69

70 **Objective:** To investigate the frequency of ISNA in different MCI types, and to evaluate for each
71 MCI type the cross-sectional relation between ISNA and white matter hyperintensities (WMH),
72 lacunes, caudate atrophy, and ventricular enlargement.

73

74 **Methods:** 1,250 subjects with different MCI types were included in the analysis, and underwent
75 brain MRI. WMH were assessed through two visual rating scales. Lacunes were also rated. Atrophy
76 of the caudate nuclei and ventricular enlargement were assessed through the bicaudate ratio (BCr)
77 and the lateral ventricles to brain ratio (LVBr), respectively. Apolipoprotein E (APOE) genotypes
78 were also assessed. The routine neurological examination was used to evaluate ISNA that were
79 clustered as central-based signs, cerebellar-based signs, and primitive reflexes. The items of Part-III
80 of the Unified Parkinson's Disease Rating Scale were used to evaluate ISNA that were clustered as
81 mild parkinsonian signs. Associations of ISNA with imaging findings was determined through
82 logistic regression analysis.

83

84 **Results:** The ISNA increase with the age, are present in all MCI types, particularly in those
85 multiple domains, and carrying the APOE $\epsilon 4$ allele, and are associated with WMH, lacunes, BCr,
86 and LVBr.

87

88 **Conclusion:** This study demonstrates that cortical and subcortical vascular and atrophic processes
89 contribute to ISNA. Long prospective population-based studies are needed to disentangle the role of
90 ISNA in the conversion from MCI to dementia.

91

92

93

94

95

96

97 **Keywords:** Isolated, subtle, neurological abnormalities, Mild cognitive impairment types, White matter
98 hyperintensities, Lacunes, Caudate atrophy, Global cerebral atrophy
99
100
101
102
103
104 Running title: ISNA in MCI types.
105
106
107
108
109
110
111 Words count of the title: 9
112 Words count of the title page: 132
113 Words count of the abstract: 247
114 Words count of the keywords: 18
115 Words count of the Introduction: 651
116 Words count of the Methods:1178
117 Words count of the Results: 1747
118 Words count of the Discussion:1189
119 Words count of the Conclusion:114
120 Words count of the body of the manuscript: **4879**
121
122 Total words of the manuscript: 5,277

123 INTRODUCTION

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

Mild cognitive impairment (MCI) is a term that refers to a condition in which an essentially spared global cognition, and normal or slightly impaired activities of daily living coexist with a mild decline of cognitive functions greater than that expected for age and education.^{1,2} Four MCI phenotypes have been recognized² as follows: amnesic MCI single domain (a-MCI), amnesic MCI multiple domain (a-MCI_{md}), nonamnesic MCI single domain (na-MCI), and nonamnesic MCI multiple domain (na-MCI_{md}). Extracellular deposition of β -amyloid ($A\beta$) peptide, intracellular deposition of hyperphosphorylated tau protein, and atrophy of frontal, parietal, and medial temporal cortices, *i.e.* neurodegeneration of AD signature cortical regions,³ are the key elements of the pathophysiology of Alzheimer disease (AD),⁴ and MCI due to AD.⁵ The prevalence of $A\beta$ positivity among subjects with MCI increases from age 50 to 90 years from 27% to 71%; nonamnesic MCI types have lower prevalence estimates of $A\beta$ positivity than amnesic MCI types, but higher than subjects cognitively normal (CN), and both amnesic and nonamnesic MCI are at increased risk for AD.⁶ Concerning tau, MCI and AD individuals have tau accumulation in the basal and mild-temporal, retrosplenial, posterior cingulate, and entorhinal regions greater than CN individuals $A\beta$ positive.⁷

The observation that 21,5% and 35% of individuals with amnesic and nonamnesic MCI types, respectively, are $A\beta$ negative,⁸ has suggested that these individuals are not on the AD pathway, and that vascular pathology may be one of the possible non-AD causes of MCI. Among vascular pathology, cerebral small vessel disease (SVD) plays a pivotal role. SVD affects the smallest cerebral small vessels, increases throughout the lifespan,⁹ and contributes to the risk of MCI,¹⁰ and dementia.¹¹ White matter hyperintensities (WMH), lacunes, small subcortical infarcts, microbleeds, enlarged perivascular spaces, and central atrophy are the imaging markers of SVD.¹² Lacunes¹³ and WMH¹⁴ disrupting locally the structural integrity of white matter induce thinning of the connected cortical regions through Wallerian degeneration. Lacunes are associated with widespread cortical thinning, atrophy in multiple subcortical structures, and ventricular enlargement.¹⁵ In subjects with MCI, expansion of the lateral ventricles is associated with atrophy of frontal, parietal, and temporal regions affected by AD.¹⁶ Furthermore, age *per se* is associated with atrophy of the cerebellum, striatum, and prefrontal, parietal, and temporal association cortices.¹⁷ The pattern of cortical atrophy induced by severe WMH overlaps substantially with the patterns of age-related cortical atrophy and of AD-related cortical atrophy.¹⁸ Since cortical

154 atrophy induced by WMH drives cognitive decline,¹⁹ age and SVD may contribute to the onset of
155 cognitive decline through the overlapping atrophy of cortical regions vulnerable to AD pathology.

156 Cerebral SVD, A β , tau, and atrophic changes fragmenting over time brain networks into
157 disconnected parts not only contribute to cognitive decline, but also contribute to the presentation of a
158 wide range of neurological signs. We have shown that neurologically and cognitively healthy (NCH)
159 aging subjects frequently present at the routine neurological examination isolated, subtle, neurological
160 abnormalities (ISNA) which do not have any immediate diagnostic relevance, cannot be attributed to any
161 definite, overt neurological disease, are associated with atrophy of the caudate nuclei, and with parietal
162 WMH and lacunes, and probably constitute a red flag for future cognitive decline given that they show
163 poor performance in test evaluating global cognition, executive function, and language.²⁰ Past reports on
164 neurological signs in MCI have primarily focused on extrapyramidal features,^{21,22} while reports on signs
165 others than extrapyramidal are sparse. Therefore, the aims of our study are: 1) to investigate the
166 prevalence of ISNA in the 4 MCI types; 2) to verify whether in the individual MCI types the
167 probability of having ISNA is differently associated with the topographical location of WMH and
168 lacunes, periventricular WMH (WMH-PV), APOE ϵ 4 allele, and with two linear measures of central
169 atrophy,¹² *i.e.* the bicaudate ratio (BCr) as proxy of subcortical atrophy, and the lateral ventricles to brain
170 ratio (LVBr) as proxy of global brain atrophy. In the present paper, the terms “adult”, “elderly”, “old”,
171 and “oldest-old” will be used to indicate people aged 45-64, 65-74, 75-84, and >85 years respectively.

172

173

174 **METHODS**

175 **Participants**

176 Data were used from the Cognitive Impairment through Aging (CogItA) study, a hospital-based
177 prospective study focused on normal and pathological aging in middle-aged and older individuals
178 launched in January, 2000. CogItA’s participants were outpatients self-referred or referred by general
179 practitioners for neurological and/or cognitive screenings to the clinics of the Department of Neurology
180 and Cognitive Disorders of the teaching Hospital (AOUP “P.Giaccone”) of the School of Medicine of the
181 University of Palermo, Italy. Details of the inclusion and exclusion criteria of the CogItA study have been
182 reported elsewhere.²⁰ Informed consent was obtained from all participants and relatives. The study was
183 approved by the University Hospital ethics committee, and complies with the declaration of Helsinki.

184 According to the published criteria,^{1,2} CogItA participants with preserved global cognition at the
185 Mini-Mental State examination (MMSE score $\geq 23,74$),²³ subjective cognitive concerns, objective
186 impairment in one or more cognitive domains, Clinical Dementia Rating (CDR) = 0.5,²⁴ no impaired or
187 minimally impaired functional status on the activities of daily living (ADL)²⁵ and the instrumental
188 activities of daily living (IADL) ²⁶ scales, and no dementia were classified as MCI and categorized as a-
189 MCI, a-MCI_{md}, na-MCI, and na-MCI_{md}. MCI subjects included in the present paper were stroke-free
190 first ever diagnosed cases (n=1,250) aged 45-95 years (mean age = 70,52 \pm 9,41 years), who remained in
191 the MCI status for at least 3 years (mean follow-up = 64,98 \pm 28,94 months). During this period, some of
192 these subjects changed their MCI typology, but in the present paper first-ever MCI diagnoses were
193 considered. Subjects who during the follow-up reverted to normal cognition, or converted to dementias
194 different from AD and Vascular Dementia (VaD) were not considered.

195

196 **Baseline Clinical Assessment**

197 Participants to the present study underwent an extensive assessment of variables such as
198 demographics, medical history, laboratory tests, neurological, and functional examinations, cognitive
199 testing, carotid ultrasonography, and brain magnetic resonance imaging (MRI). Many vascular risk
200 factors (VRF) and vascular diseases (VD) were considered and assessed as reported elsewhere.^{20,29} Since
201 multiple VRF and VD often coexist, we created the VRF and VD summary scores indicating for each
202 participant the sum of the individual VRF and VD that were concurrently present. APOE genotypes were
203 determined by using standard methods.³⁰ Participants with at least 1 APOE ϵ 4 allele were classified as
204 APOE ϵ 4 carriers.

205

206 **Assessment of ISNA**

207 All participants underwent a standardised neurological examination reflecting that routinely
208 performed in the clinical practice. Subjects presenting at baseline or during follow-up meaningful
209 neurological signs such as visual field defects, language deficits, cranial nerves deficits, hemimotor and
210 hemisensory dysfunction, brachial or crural weakness, brachial or crural sensory dysfunction, Babinski
211 sign, spastic rigidity, and hemiplegic gait were excluded. The ISNA evaluated were: 1) mild dysphagia, 2)
212 slurred speech, 3) central facial weakness, 4) mixed rigidity, *i.e.* a condition in which spastic and plastic
213 rigidity coexist; 5) hyperreflexia (bilateral increased deep tendon reflexes), 6) reflex asymmetry, 7)

214 tremor (resting tremor, and postural/kinetic tremor), 8) plastic rigidity, 9) bradykinesia, 10)
215 gait/balance/axial dysfunction, 11) dysmetria, 12) atactic type gait defined as a gait pattern broadly
216 indicative of cerebellar involvement, and 13) primitive reflexes (PR) *i.e.* glabellar tap, snout,
217 palmomental, grasping, and sucking reflexes.^{31,32} To evaluate tremor, rigidity, bradykinesia, and
218 gait/balance/axial dysfunction, collectively called Mild Parkinsonian Signs (MPS),³³ the items of motor
219 section of the Unified Parkinson's Disease Rating Scale (UPDRS)³⁴ were used, and were considered
220 present when any one of the following condition was met: (1) two or more items with a score of 1; or (2)
221 one item with a score ≥ 2 .²¹ The ISNA were dichotomised as absent (score = 0) or present (score = 1), and
222 were clustered into four categories as following: central-based signs (Cs) (signs 1-6), Mild Parkinsonian
223 Signs (MPS) (signs 7-10), cerebellar-based signs (CLs) (signs 11-12), and PR (signs 13). We defined the
224 presence of Cs, MPS, CLs, and PR as the presence of at least one sign within those included in each of
225 these clusters. Accordingly, subjects were divided into subjects without ISNA (ISNA-), and with ISNA
226 (ISNA+) if at least one sign within the above clusters was present. The neurological examination of each
227 participant was always performed by two neurologists blinded to the patients history and neuroimaging.
228 The interrater reliability assessed over time in random samples showed always excellent agreement with
229 weighted Cohen's kappa ranging between 0.88 and 0.91 ($p < 0.001$).

230

231 **Functional and Neuropsychological Assessments**

232 The functional status of participants was assessed through the ADL and the IADL scales. Cognitive
233 functions were assessed using an extensive neuropsychological battery as reported elsewhere,^{20,35}
234 including the MMSE as test of global cognition, and 12 tests to evaluate memory, attention, executive
235 function, language, constructional ability, and visuospatial skill. Impaired cognitive domains were
236 identified using a cut-off of 1,5 standard deviation (SD)² below the Italian normative data adjusted for
237 age-, sex-, and education.³⁶

238

239 **Carotid Ultrasonography and Imaging Assessments**

240 Intimal-medial thickness (IMT), and stenosis of internal carotid arteries (SICA) were assessed as
241 reported elsewhere.²⁰ Participants had brain MRI on a 1,5T scanner (GE Signa HDxt, Milwaukee, WI,
242 USA). Details of the image acquisition protocol have been published previously.²⁰ The BCr and the
243 LVBr were calculated as reported elsewhere.^{20,35} WMH, and lacunes were assessed according to the

244 published criteria.¹² The Wahlund scale (range 0-3)³⁷ was used to obtain the scores of WMH of the
245 frontal, parieto-occipital, and temporal areas (WMH-SC), infratentorial (WMH-INF), basal ganglia
246 (WMH-BG), and the WMH total score (WMH-T). To define the WMH status, a cut-off score ≥ 2 in at
247 least one of the above regions was used. WMH-PV were evaluated with the Fazekas scale (range 0-3),³⁸
248 and a cut-off score ≥ 2 was used. Lacunes were assessed topographically according to the Wahlund
249 regions used to score WMH, and categorized as lacunes-SC, lacunes-BG, lacunes-INF, and lacunes-T. A
250 cut-off score ≥ 2 in at least one of the Wahlund regions was used to define the status of lacunes. Subjects
251 having WMH and/or lacunes with a score ≥ 2 in at least one of the Wahlund scale topographical locations
252 were categorized as SVD positive (SVD+), and those having WMH and/or lacunes with a score ≤ 1 were
253 categorized as SVD negative (SVD-).

254

255 **Statistical Analysis**

256 Descriptive statistics (percentages, mean and SD, median and IQR) were used to summarise data.
257 Continuous variables were compared between subjects ISNA- and ISNA+ by using one-way analysis of
258 variance (ANOVA), and differences were tested with a post hoc F-test. Categorical variables were
259 evaluated by contingency tables, and the hypotheses of independence were tested with χ^2 test. Logistic
260 ridge regression models³⁹ were used to evaluate for each MCI type the risk of having ISNA covarying for
261 age, sex, years of education, and the variables found significant in the univariate analysis. In general,
262 ridge regression method is the most applied solution for addressing problems of multicollinearity.⁴⁰ It
263 implies adding a small positive constant (λ), *i.e.* the ridge parameter, to the main diagonal elements of the
264 information matrix. The ridge parameter was selected using likelihood cross-validation.⁴¹ IMT, BC_r, and
265 LVBr values were scaled to work on percentage of increments. All tests were two-tailed, and statistical
266 significance was set at $p \leq 0.05$. Results are presented as odds ratios (ORs) with 95% confidence interval
267 (95% CI). All analyses were performed using R statistical software (version 3.5.1; The R Foundation for
268 Statistical Computing).

269

270

271 **RESULTS**

272 The demographic characteristics of the MCI types are shown in Table 1. In almost all MCI types,
273 the majority of subjects were elderly followed by old, adult, and oldest-old individuals. The MCI types

274 single domain were more common among the adults, while those multiple domain were more common
275 within the elderly, old, and oldest old participants. In each age class, the mean age didn't vary
276 significantly among the various MCI types. Since the oldest old subjects were few, subsequent analysis
277 was conducted pooling the old and oldest old classes in the class of old-oldest old.

278 Within the sample, 175 (14.0%) subjects didn't show any of the selected ISNA, while 1,075
279 (86.0%) presented at least one ISNA (Table 2). Overall, subjects ISNA- were more common among the
280 MCI types single domain, and subjects ISNA+ were more common among those multiple domain.
281 Primitive reflexes were the most frequent ISNA, followed by ISNA central-based, and mild parkinsonian
282 signs, while ISNA cerebellar-based were the rarest. PR were exhibited by 864 subjects (69.1%) of the
283 sample, and were more common among the MCI types multiple domain than those single domain. In all
284 MCI types, snout reflex was the most common PR followed by glabellar tap, and palmomentary reflex,
285 while grasping and sucking reflexes were the rarest. Snout and palmomentary reflexes were more common
286 among the MCI types multiple domain than those single domain, while glabellar tap was more common
287 among the amnesic MCI types than the nonamnesic types. The mean number of PR was greater among
288 the amnesic MCI types than the nonamnesic types. Central-based signs were exhibited by 645 subjects
289 (51,6%) of the sample. Subjects with Cs were more common among the nonamnesic MCI types than the
290 amnesic types. In all MCI types, reflex asymmetry was the most common Cs, followed by bilateral
291 hyperreflexia, central facial weakness, mixed rigidity, slurred speech, and dysphagia. Reflex asymmetry,
292 bilateral hyperreflexia, and central facial weakness were more common among the nonamnesic MCI
293 types than the amnesic types, while the frequency of the other Cs didn't vary among the 4 MCI types.
294 The mean number of Cs was greater among the nonamnesic MCI types than the amnesic types. Mild
295 Parkinsonian Signs were found in 46,2% (n=578) of the sample. In all MCI types, bradykinesia was the
296 most common MPS, followed by gait/balance/axial dysfunction, and tremor, while rigidity was the rarest.
297 Individual MPS were more common among the MCI types multiple domain than the MCI single domain.
298 The mean number of MPS was greater in the former than in the latter. Cerebellar-based signs were the
299 rarest ISNA encountered. Dysmetria was the most common CLs, and the atactic type gait was the rarest.
300 The frequency of dysmetria didn't vary among the 4 MCI types, while the atactic type gait was more
301 common among the a-MCI_{md} than the other MCI types. The mean number of CLs didn't vary among the
302 MCI types.

303 ISNA increased with age reaching a peak in the old-oldest old individuals (Table 3). Among the
 304 adults, 210 subjects (65,8%) were ISNA+, and 109 subjects (34,2%) were ISNA-. PR were the most
 305 frequent ISNA followed by Cs, MPS, and CLs categories. PR, Cs, and MPS were more common among
 306 the MCI types multiple domain than those single domain, while CLs didn't vary in the 4 MCI types. The
 307 mean number of ISNA was greater in the former than in the latter. Within the elderly, 405 subjects
 308 (88,4%) were ISNA+, and 53 subjects (11,6%) were ISNA-. The frequency of subjects ISNA+ didn't
 309 vary among the 4 MCI types. PR were the most frequent ISNA followed by Cs, MPS, and CLs categories.
 310 PR were almost equally distributed in the 4 MCI types, MPS and CLs were more common among the
 311 MCI types multiple domain, and Cs were more common among the nonamnestic MCI types. The mean
 312 number of ISNA was greater in the nonamnestic MCI types, than in the amnestic types. Among the old-
 313 oldest old subjects, 461 individuals (97,5%) presented at least one ISNA, and 12 individuals only (2,5%)
 314 were ISNA-. CLs and MPS didn't vary among the 4 MCI types. Cs were significantly more common
 315 among the nonamnestic MCI types, while PR were significantly more common among the amnestic MCI
 316 type. The mean number of ISNA was significantly greater in the na-MCIInd type than in the other MCI
 317 types. The co-occurrence of multiple ISNA increased with age in all MCI types.

318 Baseline characteristics of MCI types ISNA+ and ISNA- are shown in Table 4. In all MCI types, no
 319 difference was found in the distribution of female and male among the two ISNA groups. In all MCI
 320 types, the mean age of female was greater in subjects ISNA+ than in subjects ISNA-, while the mean
 321 age of male was greater in subjects ISNA+ than in subjects ISNA- in the a-MCI only. Level of education
 322 didn't vary among the ISNA groups in MCI types single domain and in a-MCIInd type, while in the na-
 323 MCIInd type subjects ISNA+ were less educated than subjects ISNA-. The ADL scores were worse in
 324 the MCI types single domain ISNA+ only, and the IADL scores were worse in the MCI types single
 325 domain and a-MCIInd ISNA+. In the na-MCIInd type, ADL and IADL scores didn't vary among the two
 326 ISNA groups. Out of the VRF evaluated, arterial hypertension only was significantly more common
 327 among subjects ISNA+ than subjects ISNA- with the na-MCIInd type, while no difference was found in
 328 the distribution of VRF among the two ISNA groups of the other MCI types. However, in a-MCI and na-
 329 MCIInd, the VRF summary score was greater in subjects ISNA+ than those ISNA-. No difference was
 330 found in the frequency of the VD evaluated among subjects ISNA+ and ISNA- of almost all MCI types,
 331 with the exception of history of TIA that was significantly more common among the subjects a-MCI
 332 ISNA+. The VD summary score was greater in subjects ISNA+ than in those ISNA- in the a-MCI only.

333 In the a-MCI type, APOE ϵ 4 carriers were significantly more common in subjects ISNA+ than in subjects
334 ISNA-, and APOE ϵ 4 non carriers were significantly more common in subjects ISNA- than in subjects
335 ISNA+. The distribution of APOE ϵ 4 carriers and non carriers didn't differ in the two ISNA groups of the
336 other MCI types.

337 Neuropsychological performances of MCI types ISNA+ and ISNA- are summarized in Table 5. The
338 MMSE score was above the cut-off level in all MCI types, but subjects a-MCI ISNA+ performed
339 significantly less than subjects ISNA-. As expected, a worse performance on memory task was exhibited
340 by the amnesic MCI types ISNA+ and ISNA-. In subjects with a-MCI, the nonmemory domains were not
341 impaired, but subjects ISNA+ performed significantly less than subjects ISNA- in attention, executive
342 function, and language. In subjects a-MCI_{md} ISNA+ and ISNA-, the nonmemory domains were
343 impaired, and subjects ISNA+ performed significantly worse than subjects ISNA- in tests evaluating
344 language. In the nonamnesic MCI types no significant difference was found in the performance of
345 nonmemory domains among subjects ISNA+ and ISNA-, although a trend of worse performance of
346 subjects ISNA+ in almost all cognitive domains was evident.

347 Carotid ultrasonography and imaging findings in the MCI types ISNA+ and ISNA- are reported in
348 Table 6. In all MCI types, the frequency of IMT was significantly higher in subjects ISNA+ than
349 subjects ISNA-, while the frequency of SICA didn't differ between the two ISNA groups. In a-MCI, na-
350 MCI, and na-MCI_{md}, WMH-SC, WMH-T, and WMH-PV were significantly higher in subjects ISNA+
351 than subjects ISNA-, while in a-MCI_{md} WMH-BG only were significantly higher in subjects ISNA+.
352 Lacunes-BG and lacunes-T were significantly higher in MCI types single domain ISNA+, and lacunes-T
353 were significantly higher in na-MCI_{md} ISNA+. In a-MCI, na-MCI, and na-MCI_{md}, SVD+ was more
354 common in subjects ISNA+ than ISNA-, while SVD- was more common among the subjects ISNA- than
355 ISNA+. In a-MCI_{md}, the distribution of subjects SVD+ and SVD- didn't differ among the two ISNA
356 groups. BCr was significantly higher in all MCI types ISNA+ with the exception of a-MCI_{md} type. LVBr
357 was significantly higher in the MCI types single domain ISNA+, while no difference among the ISNA
358 groups was found in the MCI types multiple domains.

359 To assess the effects of the variables evaluated on the estimated probability of having at least one
360 ISNA, logistic ridge regression analysis was carried out in each MCI type (Table 7). Age resulted
361 associated with a-MCI type only. For each year of age increase, the odds of having at least one ISNA
362 went up about 3%. Being female increased by 7,7% the probability of having at least one ISNA in the a-

363 MCI type only. Education, and VRF summary score didn't influence the probability of having at least one
 364 ISNA in any of the MCI types. VD summary score increased the probability of having at least one ISNA
 365 in a-MCI (18,1%), na-MCI (11,1%), and na-MCIImd (4,5%). Being carrier of the APOE ϵ 4 allele
 366 increased by 52,7%, 16,5%, and 5,1% the probability of having at least one ISNA in a-MCI, a-MCIImd,
 367 and na-MCIImd, respectively. At the increase of a single percentage point of the IMT the probability of
 368 having at least one ISNA in a-MCI, a-MCIImd, na-MCI, and na-MCIImd went up by 52,7%, 36,9%,
 369 14,8%, and 16,3%, respectively. The presence of WMH-PV increased by 36,7%, 58,4%, and 14,3% the
 370 probability of having at least one ISNA in a-MCI, na-MCI, and na-MCIImd, respectively. The presence
 371 of SVD in the frontal region increased the risk of having at least one ISNA in a-MCI (16,4%), na-MCI
 372 (54,5%), and na-MCIImd (16%) types. The presence of SVD in the parieto-occipital region increased the
 373 risk of having at least one ISNA in a-MCI, na-MCI, and na-MCIImd by 22,3%, 30,3%, and 10,5%,
 374 respectively. The presence of SVD in the lateral temporal region increased the risk of having at least one
 375 ISNA in a-MCI, a-MCIImd, na-MCI, and na-MCIImd MCI by 14,0%, 15,9%, 19,8%, and 8,4%,
 376 respectively. The presence of SVD in the basal ganglia increased the risk of having at least one ISNA in
 377 a-MCI, a-MCIImd, na-MCI, and na-MCIImd by 29,9%, 31,1%, 51,8%, and 9,7%, respectively. BCr, and
 378 LVBr resulted associated with all the MCI types. At the increment of a single percentage point of BCr,
 379 the probability of having at least one ISNA increased by 15,6% in a-MCI, 31,9% in a-MCIImd, 65,8% in
 380 na-MCI, and 32,4% in na-MCIImd. At the increment of a single percentage point of LVBr, the odds of
 381 having at least one ISNA increased by 13,1% in a-MCI, 6,2% in a-MCIImd, 9,6% in na-MCI, and 5,2% in
 382 na-MCIImd.

383
 384
 385

DISCUSSION

386 The frequency of ISNA detected in subjects with MCI was greater (86%) than that found in NCH
 387 aging individuals (57,2%).²⁰ In all MCI types, and in all age classes, PR were the ISNA most frequently
 388 encountered, followed by Cs, MPS, and CLs. All ISNA categories increased with age, and were presented
 389 by both the amnesic and nonamnesic MCI types, particularly by those multiple domain, with the
 390 exception of Cs and PR that in the old-oldest old subjects were more common among the MCI types
 391 single domain.

392 Copious data of the literature underline the importance of midlife vascular risks and A β burden to
 393 neurodegenerative processes, and to the development of cognitive decline in older adults. In CN

394 individuals, midlife VRF accelerate structural brain aging,⁴² are associated with greater prospective
395 cognitive decline,⁴³ current and later-life smaller brain volumes,⁴⁴ and risk of dementia.⁴⁵ Further, midlife
396 but not later-life exposure to VRF is important also for A β deposition, as shown by the fact that having 2
397 or more midlife VRF compared with none is significantly associated with elevated A β deposition (61.2%
398 vs 30.8%).⁴⁶ In addition, in CN and MCI individuals, VRF interact with A β to reduce cortical thickness
399 in frontotemporal and parietal regions vulnerable to AD,⁴⁷ and are associated with prospective cognitive
400 decline, both alone and synergistically with A β burden.⁴⁸ However, VRF summary score was not
401 associated with ISNA in any of the 4 MCI types, and VD summary score increased the probability of
402 having at least one ISNA in the MCI types single domain, and poorly in the na-MCI_{md}. These data need
403 attention. A high vascular risk burden at younger ages is indeed indicative of early vascular aging,⁴⁹ but in
404 the later years of life it is less relevant regarding the MCI typology since vascular and neurodegenerative
405 processes have already occurred at younger ages when the MCI typology is likely to be of single domain
406 type. The fact that subjects with MCI types multiple domain were older than subjects with MCI types
407 single domain supports this hypothesis. IMT increased the probability of having at least one ISNA in all
408 MCI types, and the risk was greater for the amnesic MCI types than for the nonamnesic types. These
409 results are in agreement with a previous study showing that IMT is associated with WMH, infarcts, brain
410 atrophy, and with poor cognitive performance particularly in the executive function.⁵⁰ Further, IMT
411 significantly increases the risk of conversion of a-MCI to dementia.⁵¹ WMH-PV increased greatly the
412 probability of having at least one ISNA in MCI types single domain, and in the na-MCI_{md}. It has been
413 shown that WMH-PV are associated with elevated A β deposition independently from age and presence of
414 APOE ϵ 4 allele,⁵² and induce thinning of prefrontal, parietal, temporal cortices, anterior insula, and
415 atrophy of the caudate nuclei,¹⁴ and cognitive decline through the cortical atrophy of the above
416 disconnected regions.¹⁹ Therefore, it is reasonable to suspect that even in our MCI types WMH-PV may
417 also have induced atrophy of the caudate nuclei, and thinning of the frontal, parietal, and temporal
418 cortices through likely disruption of periventricular long associating tracts.

419 Overall, SVD at different topographical locations, and BCr greatly increases the risk of having
420 ISNA in all the MCI types. Given that cortex, cerebellum, and BG are strictly interconnected,⁵³ it is
421 likely that ISNA are the by-product of the disconnection of the cortical-cerebellar-basal ganglia-thalamo-
422 cortical circuits induced by vascular and degenerative processes. It is also likely that the caudate atrophy
423 and the disruption of the internal circuits of BG may have induced an excessive inhibition to its output

424 nuclei. As a consequence, the inhibitory drive to thalamus may have led to bradykinesia, and that to
425 brainstem structures controlling postural muscle tone and locomotion may have led to rigidity and
426 gait/balance/axial dysfunction respectively,⁵⁴ while the inhibition of the physiological inhibitor control of
427 lower brainstem centres on stereotyped motor responses⁵⁵ may have led to the reappearance of PR.

428 Nevertheless, the above hypotheses underpinning the vascular contribution to ISNA do not fully
429 explain their presentation in the various MCI types. Among the amnesic MCI types, 39% (n=342) of
430 subjects ISNA+ were SVD-, and 5% (n=45) of subjects ISNA- were SVD+. Similarly, among the
431 nonamnesic MCI types 51% (n=190) of subjects ISNA+ were SVD-, and 35% (n=130) of subjects
432 ISNA- were SVD+. These conflicting data suggest that co-occurring factors others than vascular
433 contribute to the presentation of ISNA. The APOE ϵ 4 allele can be one of these factors. In the present
434 study, the APOE ϵ 4 carriers were indeed over-represented relative to other studies, probably because the
435 CogItA study assessed essentially subjects referred to the memory clinic, making the sample vulnerable
436 to selection. Overall, APOE ϵ 4 carriers were more common among subjects ISNA+ than subjects ISNA-
437 in all MCI types, and being ϵ 4 carrier increased the probability of having at least one ISNA greatly in the
438 amnesic MCI types and scarcely in the nonamnesic MCI types, a finding in agreement with the notion
439 that compared to non ϵ 4 carriers, MCI ϵ 4 carriers have frequently the amnesic phenotype.⁵⁶ The presence
440 of APOE ϵ 4 allele in nonamnesic MCI types is not surprising. Along with age, APOE ϵ 4 allele is a
441 significant predictor of amyloidosis. More than half of all MCI types is A β positive,⁵⁷ and APOE ϵ 4
442 carriers are 2-3 times more likely to be amyloid positive than APOE ϵ 4 non carriers.⁶ Subjects with MCI
443 have elevated A β deposition in frontal, parietal, temporal, and posterior cingulate cortices suggestive of
444 early AD process,⁵⁸ and those converting to AD have a greater A β deposition in these regions, as well as
445 in the putamen and in the caudate nuclei as compared to nonconverters.⁵⁹ Furthermore, in subjects with
446 MCI the presence of the APOE ϵ 4 allele is more frequent in the converters than in the nonconverters.⁶⁰
447 Therefore, it is reasonable to suspect that subjects of all 4 MCI types carrying the APOE ϵ 4 allele were
448 also A β positive, and that subjects ISNA+ being more APOE ϵ 4 carriers than subjects ISNA- were
449 candidates to convert to dementia faster than subjects ISNA-.

450

451 **Limitations of the study**

452 Some limitations of our study are worth noting. First, CSF biomarkers of A β and tau, and
453 advanced imaging techniques up to now are not fully available in our country, particularly in a clinical

454 setting. So, we do not know the distribution of A β and tau in subjects ISNA+ and ISNA- of the various
455 MCI types. Second, we assessed cortical and subcortical atrophy using linear measurements well aware
456 that they are rather crude estimates of brain atrophy. However, it has been shown that the bicaudate ratio
457 is a reliable marker of caudate atrophy,⁶¹ and that ventricular enlargement is a feasible, even if
458 nonspecific, surrogate marker of neurodegeneration in MCI and AD.¹⁶ Third, we didn't estimate WMH
459 volumetrically, but visually. However, it has been shown that WMH evaluated with visual scales correlate
460 well with WMH volumetry.⁶² Fourth, perhaps we underestimated the magnitude of cerebral SVD in our
461 cohort, because we evaluated WMH and lacunes only. Fifth, the generalizability of our results is limited
462 because the patients have been selected in a hospital setting. **Sixth, in the present paper there is not**
463 **mention of the ISNA in neurologically and cognitively normal subjects because data on this topic**
464 **has been already published.**²⁰ Lastly, the cross-sectional design of our study doesn't allow causal
465 inferences.

466

467 CONCLUSION

468 ISNA are likely to have a multifactorial origin, increase with age, and are presented by both the
469 amnesic and nonamnesic MCI types, particularly by those multiple domain, and carrying the APOE ϵ 4
470 allele. Further, subjects ISNA+ perform less than subjects ISNA- in almost all nonmemory domains.
471 Given that cortical and subcortical vascular and atrophic processes contribute to ISNA, their presence in
472 individuals with MCI must alert the practitioners to target timely interventions to slowing cognitive
473 decline and delay progression of MCI to dementia. Longer prospective population-based studies are
474 needed to clarify to what extent the presentation of ISNA in middle-aged and older MCI individuals
475 represents an additive risk for the conversion to dementia.

476

477

478

479

480

481

482

483

484 **ACKNOWLEDGEMENTS**

485 We gratefully thank all participants, as well as the neurologists and the neuropsychologists who over time
486 collected patients data.

487

488 **STATEMENT OF AUTHORSHIP**

489 CC and RC were responsible for the study's concept and design, data managements, and record linkage.

490 GS and GC did the statistical analysis. CC, PT, CP, DA, and RC contributed to the analysis and
491 interpretation of the data.

492 CC wrote the paper. All co-authors edited the paper, and approved its final version.

493

494

495 **DISCLOSURES**

496 All the authors hereby declare that they have nothing to disclose.

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

REFERENCES

532

1. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. *Arch Neurol.* 1999; 56:303-308.
2. Petersen RC. Mild cognitive impairment as a diagnostic entity. *J Intern Med.* 2004; 256:183-194.
3. Jack RC Jr. Brain Atrophy on Magnetic Resonance Imaging as a Biomarker of Neurodegeneration. *JAMA Neurol.* 2006; 73:1179-1182.
4. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guide-lines for Alzheimer's disease. *Alzheimers Dement.* 2001; 7: 263-269.
5. Albert MS, Dekosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging and Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement.* 2011; 7:270-279.
6. Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FR, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. *JAMA* 2015; 313:1924-1938.
7. Jack CR Jr, Wiste HJ, Schwarz CG, Lowe VJ, Senjem ML, Vemuri P, et al. Longitudinal tau PET in ageing and Alzheimer's disease. *Brain.* 2018; 141: 1517-1528.
8. Petersen RC, Aisen P, Boeve BF, Geda YE, Ivnik RJ, Knopman DS, et al. Criteria for mild cognitive impairment due to Alzheimer disease in the community. *Ann Neurol.* 2013; 74:199-208.
9. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. *Lancet Neurol.* 2010; 9: 689-701.
10. Luchsinger JA, Brickman AM, Reitz C, Cho SJ, Schupf N, Manly JJ, et al. Subclinical cerebrovascular disease in mild cognitive impairment. *Neurology.* 2009; 73:450-456.
11. Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke.* 2011; 42:2672-2713.
12. Wardlaw JM, Smith C, Biessels GJ, Cordonnier C, Fazekas F, Frayne R, et al. Neuroimaging standards

- for research into small vessel disease and its contribution to ageing and neurodegeneration. *Lancet Neurol.* 2013; 12: 822-838.
13. Reijner YD, Freeze WM, Leemans A, Biessels GJ. The effect of lacunar infarcts on white matter tract integrity. *Stroke.* 2013; 44:2019-2021.
 14. Lambert C, Narean JS, Benjamin P, Zeestraten E, Barrick TR, Markus HS. Characterising the grey matter correlates of leukoaraiosis in cerebral small vessel disease. *Neuroimage Clin.* 2015; 9:194-205.
 15. Thong JY, Hilal S, Wang Y, Soon HW, Dong Y, Collinson SL, et al. Association of silent lacunar infarct brain atrophy and cognitive impairment. *J Neurol Neurosurg Ps.* 2013; 84:1219-1225.
 16. Madsen SK, Gutman BA, Joshi SH, Toga AW, Jack CR Jr, Weiner MW, et al. Mapping ventricular expansion onto cortical gray matter in older adults. *Neurobiol Aging.* 2014; 36 (Suppl 1): S32-S41.
 17. Raz N, Lindenberger U, Rodrigue KM, Kennedy KM, Head D, Williamson A, et al. Regional brain changes in aging healthy adults: general trends, individual differences and modifiers. *Cereb Cortex.* 2005; 15: 1676-1689.
 18. Habes M, Erus G, Toledo JB, Zhang T, Bryan N, Launer LJ, et al. White matter hyperintensities and imaging patterns of brain ageing in the general population. *Brain.* 2016; 139: 1164-1179.
 19. Rizvi B, Narkhede A, Last BS, Budge M, Tosto G, Manly JJ, et al. The effect of white matter hyperintensities on cognition is mediated by cortical atrophy. *Neurobiol Aging.* 2018; 64: 25-32.
 20. Camarda C, Torelli P, Camarda R, Battaglini J, Gagliardo C, Monastero R. Isolated, Subtle, Neurological Abnormalities in Neurologically and Cognitively Healthy Aging Subjects. *J Neurol.* 2015; 262:1328-1339.
 21. Louis ED, Schupf N, Manly J, Marder K, Tang MX, Mayeux R. Association between mild parkinsonian signs and mild cognitive impairment in a community. *Neurology.* 2005; 64:1157-1161.
 22. Boyle PA, Wilson RS, Aggarwal NT, Arvanitakis Z, Kelly J, Bienias JL, et al. Parkinsonian signs in subjects with mild cognitive impairment. *Neurology.* 2005; 65:1901-1906.
 23. Folstein MF, Folstein SE, McHugh PR. Mini-mental State: a practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res.* 1975; 12:189-198.
 24. Morris JC. Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. *Int Psychogeriatr.* 1997; 9:173-176.
 25. Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the aged. The index of

- ADL: a standardized measure of biological and psychosocial function. *JAMA*. 1963; 185: 914-919.
26. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. *Gerontologist*. 1969; 9:179-186.
 27. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. *J Alzheimers Dis*. 2006; 9: 417-423.
 28. Brun A, Englund B, Gustafson L, Passant U, Mann DMA, Neary D, et al. Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups. *J Neurol Neurosurg Psychiatry*. 1994; 57: 416-418.
 29. Camarda C, Torelli P, Pipia C, Azzarello D, Battaglini I, Sottile G, Cilluffo G, Camarda R. Nociceptive primitive reflexes in neurologically and cognitively healthy aging subjects. *Canad J Neurol Sci*. 2019; 46:199-208.
 30. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. *J Lipid Res*. 1982; 31: 545-548.
 31. Rossor MN. Snouting, potting and rooting. *Pract Neurol*. 2001; 1:119-121.
 32. Schott JM, Rossor MN. The grasp and other primitive reflexes. *J Neurol Neurosurg Psychiatry*. 2003; 74:558-560.
 33. Louis ED, Bennett DA. Mild Parkinsonian Signs: an overview of an emerging concept. *Mov Disord*. 2007; 22:1681-1688.
 34. Fahn S, Elton RL and the members of the UPDRS development committee. Unified Parkinson's Disease Rating Scale. In Fahn S, Marsden CD, Goldstein M, Calne DB (Eds). *Recent Developments in Parkinson's Disease*. London, MacMillan Healthcare Information pp. 153-163 (1987).
 35. Camarda C, Pipia C, Azzarello D, Battaglini I, Romeo G, Chiodi M, et al. Vascular Risk Factors, Vascular Diseases, and Imaging Findings in a Hospital-based Cohort of Mild Cognitive Impairment Types. *Current Alzheimer Dis*. 2018; 15: 679-690.
 36. Carlesimo GA, Caltagirone C, Gainotti G. The Mental Deterioration Battery: normative data, diagnostic reliability and qualitative analyses of cognitive impairment: the Group for the Standardization of the Mental Deterioration Battery. *Eur Neurol*. 1996; 36: 378-384.
 37. Wahlund LO, Barkhof F, Fazekas F, Bronge L, Augustin M, Sjögren M, et al. A new rating scale for

- age-related white matter changes applicable to MRI and CT. *Stroke*. 2001; 32: 1318-1322.
38. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. *AJR Am J Neuroradiol*. 1987; 8:421-426.
 39. Hoerl AE, Kennard RW. Ridge regression: Biased estimation for nonorthogonal problems. *Technometrics*. 1970; 12: 55-67.
 40. El-Dereny M, Rashwan NI. Solving multicollinearity problem using ridge regression models. *Int J Contemp Math Sciences*. 2011; 6: 585-600.
 41. Goeman JJ. L1 penalized estimation in the Cox proportional hazards model. *Biom J*. 2010; 52:70-84.
 42. Debette S, Seshadri S, Beiser A, Au R, Himalim JJ, Palumbo C, et al. Midlife vascular risk factor exposure accelerates structural brain aging and cognitive decline. *Neurology*. 2011; 77:461-468.
 43. Gottesman RF, Schneider AL, Albert M, Alonso A, Bandeen-Roche K, Coker L, et al. Midlife hypertension and 20-year cognitive change: the atherosclerosis risk in communities neurocognitive study. *JAMA Neurol*. 2014; 71:1218-1227.
 44. Pase MP, Davis-Plourde K, Himali JJ, Satizabal CL, Aparicio H, Seshadri S, et al. Vascular risk at younger ages most strongly associates with current and future brain volume. *Neurology*. 2018; 91: 1479-1486.
 45. Whitmer RA, Gunderson EP, Quesenberry CP Jr, Zhou J, Yaffe K. Bodymass index in midlife and risk of Alzheimer disease and vascular dementia. *Curr Alzheimer Res*. 2007; 4:103-109.
 46. Gottesman RF, Schneider AL, Zhou Y, Coresh J, Green E, Gupta N, et al. Association between midlife vascular risk factors and estimated brain amyloid deposition. *JAMA*. 2017; 317:1443-1450.
 47. Villeneuve S., Reed BR, Madison CM, Wirth M, Marchant NL, Kriger S, et al. Vascular risk and A β interact to reduce cortical thickness in AD vulnerable brain regions. *Neurology*. 2014; 83: 40-47.
 48. Rabin JS, Schultz AP, Hedden T, Viswanathan A, Marshall GA, Kilpatrick E, et al. Interactive Associations of Vascular Risk and β -Amyloid Burden With Cognitive Decline in Clinically Normal Elderly Individuals. Findings From the Harvard Aging Brain Study. *JAMA Neurol*. 2018; 75: 1124-1131.
 49. Nilsson PM. Early vascular aging (EVA): consequences and prevention. *Vasc Health Risk Manag*. 2008; 4:547-552.
 50. Romero JR, Beiser A, Seshadri S, Benjamin EJ, Polak JF, Vasan RS, et al. Carotid artery

- atherosclerosis, MRI indices of brain ischemia, aging, and cognitive impairment: the Framingham study. *Stroke*. 2009; 40:1590-1596.
51. Viticchi G, Falsetti L, Vernieri F, Altamura C, Bartolini M, Luzzi S, et al. Vascular predictors of cognitive decline in patients with mild cognitive impairment. *Neurobiol Aging*. 2012; 33: 1127. e1-9.
 52. Marnane M, Al-Jawadi OO, Mortazavi S, Pogorzelec KJ, Wang BW, Feldman HH, et al. Periventricular hyperintensities are associated with elevated cerebral amyloid. *Neurology*. 2016; 86:1-9.
 53. Caligiore D, Strick PL, Jörntell H, Popa T, Herreros I, Pezzulo G, et al. Consensus Paper: Towards a Systems-Level View of Cerebellar Function: the Interplay Between Cerebellum, Basal Ganglia, and Cortex. *Cerebellum*. 2017; 16:203-229.
 54. Takakusaki K. Neurophysiology of gait: from the spinal cord to the frontal lobe. *Mov Disord*. 2013; 28:1483-1491.
 55. Delwaide PJ, Dijeux L. Réflexes néonataux et dyskinésies bucco-linguo-faciales dans la démence sénile. Neonatal reflexes and bucco-linguo-facial dyskinesias in senile dementia. *L'Actualité en Gériatrie*. 1980; 6:126-33.
 56. Snowden JS, Stopford CL, Julien CL, Thompson JC, Davidson Y, Gibbons L, et al. Cognitive phenotypes in Alzheimer's disease and genetic risk. *Cortex*. 2007; 43:835-845.
 57. Wolk DA, Price JC, Saxton JA, Snitz BE, James JA, Lopez OL, et al. Amyloid imaging in mild cognitive impairment subtypes. *Ann Neurol*. 2009; 65:557-568.
 58. Kemppainen NM, Aalto S, Wilson IA, Någren K, Helin S, Brück A, et al. PET amyloid ligand [C-11] PIB uptake is increased in mild cognitive impairment. *Neurology*. 2007; 68:1603-1606.
 59. Koivunen J, Scheinin N., Virta JR, Aalto S, Vahlberg T, Någren K, et al. Amyloid PET imaging in patients with mild cognitive impairment. A 2-year follow-up study. *Neurology*. 2011; 76:1085-1090.
 60. Okello A, Koivunen J, Edison P, Archer HA, Turkheimer FE, Någren K, et al. Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. *Neurology*. 2009; 73:754-760.
 61. Doraiswamy PM, Patterson L, Na C, Husain MM, Boyko O, McDonald WM, et al. Bicaudate index on magnetic resonance imaging: effects of normal aging. *J Geriatr Psych Neurol*. 1994; 7: 13-17.
 62. Gao F, Swartz RH, Scheltens P, Leibovitch FS, Kiss A, Honjo K, et al. Complexity of MRI White matter

hyperintensity assessments in relation to cognition in aging and dementia from the Sunnybrook
Dementia Study. *J Alzheimers Dis.* 2011; 26: 379-388.

533